This afternoon we watched Apexigen rise 1.8% to a price of $0.56 per share. The Small-Cap Pharmaceutical company is now trading -12.5% below its average target price of $0.64. Analysts have set target prices ranging from $0.64 to $0.64 per share for Apexigen, and have given the stock an average rating of hold.
Apexigen's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.3%. The stock's short ratio is 0.72. Insiders such as directors and executives own 7.09% of the company's shares, from which we can deduce there is a significant degree of alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 12.8%. In conclusion, we believe there is mixed market sentiment regarding Apexigen.
Institutions Invested in Apexigen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Decheng Capital Management III (Cayman), LLC | 8% | 1,894,551 | $1,060,948 |
| 2023-03-31 | Yu Fan | 2% | 401,757 | $224,983 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 1% | 256,935 | $143,883 |
| 2023-03-31 | Blackrock Inc. | 1% | 213,833 | $119,746 |
| 2023-03-31 | Geode Capital Management, LLC | 1% | 178,760 | $100,105 |
| 2023-03-31 | CVI Holdings, LLC | 1% | 150,000 | $84,000 |
| 2023-03-31 | State Street Corporation | 0% | 54,300 | $30,408 |
| 2023-03-31 | Mercer Global Advisors, Inc./ADV | 0% | 43,626 | $24,430 |
| 2023-03-31 | Northern Trust Corporation | 0% | 31,041 | $17,382 |
| 2023-03-31 | Two Sigma Investments, LP | 0% | 28,970 | $16,223 |
